This author has yet to write their bio.Meanwhile lets just say that we are proud BioSpace contributed a whooping 4797 entries.
Six months after its official launch by Flagship Ventures, Massachusetts-based Vesalius Therapeutics is laying off 43% of its staff. With a current headcount of 67, the company is slashing 29 jobs.
Both Bristol-Myers Squibb and AbbVie separately filed notices with the California state government stating they intend to lay off up to 360 people in the state.
Virios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia.
The FDA approved bluebird bio’s lentiviral vector (LVV) eli-cel Friday as the first therapy to slow the progression of neurologic dysfunction in juvenile boys with early, active cerebral adrenoleukodystrophy (CALD).
The FDA approved Mallinckrodt Pharmaceuticals’ Terlivaz (terlipressin) in adults with hepatorenal syndrome (HRS), making it the only FDA-approved drug for that indication in the U.S.
Five patients with systemic lupus erythematosus (SLE) are in remission after receiving CAR T cell therapy, according to a study published Thursday in Nature Medicine.
Two days after unveiling an executive order to boost U.S. biomanufacturing, the White House revealed plans that include $2 billion to support the initiative.
Pfizer is leveraging its funding and experience with vaccines for meningococcal, flu and RSV to further expand its presence in the field.
Non-small cell lung cancer (NSCLC) was a hot topic at the recent European Society for Medical Oncology (ESMO) Congress, where several researchers presented landmark findings, many of which are considered to be firsts. Such results portend advances that could significantly improve survival for patients with this common form of cancer.
The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.